Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics.

ABSTRACT: In molecular cancer therapeutics only 10% of known cancer gene products are targetable with current pharmacological agents. Major oncogenic drivers, such as MYC and KRAS proteins are frequently highly overexpressed or mutated in multiple human malignancies. However, despite their key role in oncogenesis, these proteins are hard to target with traditional small molecule drugs due to their large, featureless protein interfaces and lack of deep pockets. In addition, they are inaccessible to large biologicals, which are unable to cross cell membranes. Designer interference peptides (iPeps) represent emerging pharmacological agents created to block selective interactions between protein partners that are difficult to target with conventional small molecule chemicals or with large biologicals. i

SUBMITTER: Sorolla A 

PROVIDER: S-EPMC7002299 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature